De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Vera Magistroni, Mario Mauri, Deborah D’Aliberti, Caterina Mezzatesta, Ilaria Crespiatico, Miriam Nava, Diletta Fontana, Nitesh Sharma, Wendy Parker, Andreas Schreiber, David Yeung, Alessandra Pirola, Sara Redaelli, Luca Massimino, Paul Wang, Praveen Khandelwal, Stefania Citterio, Michela Viltadi, Silvia Bombelli, Roberta Rigolio, Roberto Perego, Jacqueline Boultonwood, Alessandro Morotti, Giuseppe Saglio, Dong-Wook Kim, Susan Branford, Carlo Gambacorti-Passerini, and Rocco Piazza

Disclosures: The authors would like to thank Manuela Carrera and Giuliana Laurenza for technical assistance. This work was supported by Associazione Italiana Ricerca sul Cancro (IG-14249 to CGP, IG-17727 to RP, IG-22082 to RP) and by the European Union’s Horizon 2020 Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) with grant agreement No.: 675712CGP. CGP is a member of the European Research Initiative for ALK-Related Malignancies (www.erialcl.net). JB acknowledges support from Bloodwise-UK.

Contributions: VM wrote the manuscript, designed and performed research, analyzed and interpreted data; MM designed and performed research, analyzed and interpreted data; DD, CM, IC, MN, DF, and NS performed research and analyzed data; WP, AS, DY and PW collected samples, performed research; AP performed sample preparation and next generation sequencing; PK performed standard sequencing; SR and LM performed research; SC and BS performed single cell sorting; JB, AM, GS and DWK provide samples and analyzed data; RP analyzed data, SB provide samples and critically revised the manuscript; CGP and RP conceived and designed research and interpreted data.